Retatrutide

Retatrutide is an experimental peptide that mimics three body hormones at once — GLP-1, GIP, and glucagon. One molecule engineered to switch on three metabolism-related signals.

It's generating buzz as a next-generation weight-management candidate. Researchers study how a triple signal affects body weight, liver fat, and how the body burns energy at rest.

Early human trials showed dose-related weight loss over several months. These are promising early findings, not established or approved results.

Distinguishes established clinical findings from early human trials, animal experiments, or laboratory cell culture findings. No human dosing, injection instructions, or treatment recommendations are provided.

Retatrutide is investigational and still in clinical trials. It is not approved by the FDA for any use.

BBOHC LABS research reagents are non-clinical materials. An FDA approval for a finished medicine containing the same active ingredient does not imply that BBOHC's investigational research vial is FDA-approved.

Dose-related heart-rate increase and digestive intolerance in trial data. Laboratory handling only.

• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023.

Specific citations are provided for literature context. Product purity & lot verification documentation available on request.